Product Description

Ensartinib is a potent dual ALK/MET inhibitor indicated for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously progressed on or are intolerant to crizotinib therapy.

Screeningbio‘s NCI-H2228/Ensartinib resistance cell line generated by exposing to increasing concentration of drug for certain period of time. After stable acquire resistance, cells were harvested and characterized for drug resistance by 7 days proliferation assay.

Data

Target Background

Ensartinib (X-396) is a potent next‑generation anaplastic lymphoma kinase (ALK) inhibitor that targets both wild‑type ALK and a broad spectrum of ALK resistance mutations, including L1196M, G1269A, C1156Y, and others. It inhibits ALK phosphorylation and downstream signaling cascades—such as PI3K/Akt, MAPK, and JAK/STAT—leading to cell cycle arrest and apoptosis in ALK‑positive non‑small cell lung cancer (NSCLC) and other ALK‑driven tumors. However, the development of drug resistance remains a major challenge limiting its long‑term efficacy.

Mechanistically, ensartinib resistance arises through multiple cellular adaptations. Secondary mutations in the ALK kinase domain (e.g., G1202R, E1210K, and other compound mutations that reduce drug binding affinity) are a common on‑target mechanism. Upregulation of efflux transporters such as P‑glycoprotein (MDR1/ABCB1) decreases intracellular drug accumulation, while activation of bypass signaling pathways—including EGFR, SRC, IGF‑1R, MET, and others—promotes survival independently of ALK. Additionally, activation of epithelial–mesenchymal transition (EMT), enhanced autophagy, or gene amplification of the ALK fusion also contribute to reduced drug sensitivity.

Understanding these mechanisms is critical for designing strategies to overcome resistance, such as developing ALK inhibitors with broader mutational coverage, combining ensartinib with SRC or MET inhibitors, using efflux transporter modulators, or employing patient‑derived resistant cell models to guide personalized therapy development.